Fosun International’s NextCure NXTC Stock Holding History

Fosun International’s Portfolio NXTC Stock Details NXTC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-12,500	Closed	-$2.25M	–	273
2019 Q2	$2.25M	Buy	+12,500	New	+$2.6M	0.15%	96

Other funds holding NXTC

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return

HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return

MICM

Matthews International Capital Management San Francisco, California $246M AUM 10.45% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fosun International's NXTC Position: Q3 2019 in Review

Fosun International sold out of NextCure (NXTC) in Q3 2019, closing a stake of 12,500 shares — an estimated $2.25M sold.

Fosun International first reported a position in NXTC in Q2 2019 and held it in 1 quarter. The position peaked at $2.25M in Q2 2019. 52 funds tracked by Wall St. Rank hold NXTC as of Q3 2019.

Fosun International reported no remaining NextCure position as of Q3 2019 after selling out during the quarter.
Fosun International sold 12,500 NextCure shares in Q3 2019, an estimated $2.25M.
Fosun International first reported a position in NextCure in Q2 2019 and held it in 1 quarter.
Fosun International's NextCure position peaked at $2.25M in Q2 2019.
52 funds tracked by Wall St. Rank held NextCure as of Q3 2019.

Based on Fosun International's 13F filing for Q3 2019, filed 12 Nov 2019.